Corpus Intelligence IC Memo — SELECT SPECIALTY HOSPITAL - SAN DIEG 2026-04-26 23:33 UTC
IC Memo — SELECT SPECIALTY HOSPITAL - SAN DIEG
Investment Committee Memorandum | CA | 110 beds | Grade C | EBITDA uplift $4.4M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 052044

SELECT SPECIALTY HOSPITAL - SAN DIEG

LOCATIONSAN DIEGO, CA·BEDS110·AS OFApril 26, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

SELECT SPECIALTY HOSPITAL - SAN DIEG is a 110-bed suburban community hospital in SAN DIEGO, CA with $59.9M in net patient revenue and a -9.5% operating margin. The hospital serves a payer mix of 40.4% Medicare, 3.0% Medicaid, and 56.6% commercial.

Thesis: Undervalued. Our ML models identify $4.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -9.5% to -2.2% (+736bps).

Net Revenue HCRIS$59.9M
Current EBITDA COMPUTED$-5.7M
Operating Margin COMPUTED-9.5%
Occupancy HCRIS68.6%
Revenue / Bed COMPUTED$545K
Net-to-Gross HCRIS9.1%
Distress Probability ML42.8%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
179
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -9.5% places it below the state median. Among 179 size-comparable peers (55-220 beds), the median margin is -4.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (55-220), prioritizing same-state peers. 179 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SELECT SPECIALTY HOSPITAL - SA (Target)CA110$59.9M-9.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
KFH - MANTECACA213$796.8M15.2%
CHILDRENS HOSP & RES CNTR OAKLCA155$687.9M-7.1%
KFH - WALNUT CREEKCA219$681.0M-3.4%
NORTHBAY HOSPITAL GROUPCA204$676.6M-8.2%
KFH - SAN LEANDROCA216$663.8M10.3%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
KFH - VALLEJOCA184$531.7M0.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.3M+210bp18mo
Cost to Collect4.5%2.5%$1.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$729K+122bp9mo
Clean Claim Rate88.0%96.0%$38K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.3M
Cost to Collect
$1.2M
Denial Rate Reduction
$1.2M
A/R Days Reduction
$729K
Clean Claim Rate
$38K
Total EBITDA Uplift$4.4M
Current EBITDA$-5.7M
+ RCM Uplift+$4.4M
Pro Forma EBITDA$-1.3M
Current Margin-9.5%
Pro Forma Margin-2.2%
WC Released (1x)$2.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-8.8M$6.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-8.8M$4.3M0.00x-100.0%
Bull Case9.0x11.0x$-7.9M$16.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-7.9M$15.1M0.00x-100.0%
Bear Case11.0x10.0x$-9.7M$-12.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-9.7M$-17.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 179 hospitals with 55-220 beds
  • Same-state prioritization (n=180)
  • Comp margins: P25=-21.0% / P50=-4.5% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.